Your browser doesn't support javascript.
loading
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial.
Jackson, Graham H; Pawlyn, Charlotte; Cairns, David A; Striha, Alina; Collett, Corinne; Waterhouse, Anna; Jones, John R; Wilson, Jamie; Taylor, Craig; Kishore, Bhuvan; Garg, Mamta; Williams, Cathy D; Karunanithi, Kamaraj; Lindsay, Jindriska; Jenner, Matthew W; Cook, Gordon; Russell, Nigel H; Drayson, Mark T; Kaiser, Martin F; Owen, Roger G; Gregory, Walter M; Davies, Faith E; Morgan, Gareth J.
Afiliação
  • Jackson GH; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
  • Pawlyn C; The Institute of Cancer Research, London, UK.
  • Cairns DA; The Royal Marsden Hospital NHS Foundation Trust, London, UK.
  • Striha A; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Collett C; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Waterhouse A; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Jones JR; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Wilson J; Kings College Hospital NHS Foundation Trust, London, UK.
  • Taylor C; Western Sussex Hospitals NHS Foundation Trust, Chichester, UK.
  • Kishore B; Russells Hall Hospital, Dudley, UK.
  • Garg M; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Williams CD; Leicester Royal Infirmary, Leicester, UK.
  • Karunanithi K; Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, UK.
  • Lindsay J; University Hospital of North Midlands, Stoke-on-Trent, UK.
  • Jenner MW; E1ast Kent Hospitals University NHS Foundation Trust, Canterbury, UK.
  • Cook G; University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Russell NH; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Drayson MT; Leeds Cancer Centre, University of Leeds, Leeds, UK.
  • Kaiser MF; Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, UK.
  • Owen RG; Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Gregory WM; The Institute of Cancer Research, London, UK.
  • Davies FE; The Royal Marsden Hospital NHS Foundation Trust, London, UK.
  • Morgan GJ; Haematological Malignancy Diagnostic Service (HMDS), St James's University Hospital, Leeds, UK.
Br J Haematol ; 192(5): 853-868, 2021 03.
Article em En | MEDLINE | ID: mdl-32656799
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Imunomodulação / Fatores Imunológicos Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Imunomodulação / Fatores Imunológicos Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido